The top after-market NASDAQ Stock Market gainers are: Xenoport, Bed Bath & Beyond, Immucor, Fortinet, and Tesco. The top after-market NASDAQ Stock Market losers are: Power-One, Tuesday Morning, Advanced Analogic Technologies, ISTA Pharmaceuticals, and Lincare Holdings.
A U.S. jury rejected GlaxoSmithKline's antitrust claims against Abbott Laboratories over allegations of unfair HIV drug pricing, after Britain's biggest drugmaker had asked for hundreds of millions in damages.
The top pre-market NASDAQ stock market gainers are: Green Mountain Coffee Roasters, Human Genome Sciences, Semtech, Starbucks and Atrinsic. The top pre-market NASDAQ stock market losers are: Coldwater Creek, Peet's Coffee & Tea, Canadian Solar, ARM Holdings, and SIGA Technologies.
Human Genome Sciences Inc's lupus drug is poised to win clearance this week, offering patients the first approved treatment option in a half-century and setting the company up for blockbuster sales.
The top after-market NASDAQ stock market gainers are: Netease.com, ArQule, Biogen Idec, priceline.com, and Leap Wireless International. The top after-market NASDAQ stock market losers are: AXT, InterDigital, POZEN, Calumet Specialty Products Partners, and United Online.
The Bill and Melinda Gates Foundation is helping partners in China improve child vaccines, roll out faster TB detection kits and make higher-yielding rice which it hopes can be used later in other parts of the world.
The top pre-market NASDAQ stock market gainers are: Sequenom, Whole Foods Market, Progenics Pharmaceuticals, Clearwire, and Xenoport. The top pre-market NASDAQ stock market losers are: Idenix Pharmaceuticals, EZchip Semiconductor, Amkor Technology, TriQuint Semiconductor, Akamai Technologies, and Cisco Systems.
The top after-market NASDAQ stock market gainers are: Select Comfort, Whole Foods Market, 1-800-Flowers.com, SuccessFactors, and LeCroy. The top after-market NASDAQ stock market losers are: Idenix Pharmaceuticals, Pacer International, TriQuint Semiconductor, Amkor Technology, and Akamai Technologies.
Pharma major GlaxoSmithKline Plc posted a quarterly loss hit by a massive charge to settle further litigation related to its diabetes drug Avandia, but the company raised its dividend and said it would resume its share buyback program.
Europe's drive to cut drug prices as well as U.S. healthcare reforms are likely to dampen global pharmaceutical companies' growth outlooks for 2011.
GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its profit, as it settles further claims related to Avandia and sales practices.
Novartis AG wrapped up its long-awaited buyout of the remainder of U.S.-listed eyecare group Alcon Inc for $12.9 billion, after sweetening its original offer with cash.
The top pre-market NASDAQ stock market losers are: LTX-Credence, BroadSoft, Cninsure, YRC Worldwide, Human Genome Sciences, Celgene, Identive Group, Randgold Resources, Qiagen, and Corinthian Colleges.
The top after-market NASDAQ stock market gainers are: Nova Measuring Instruments, China Biologic Products, MannKind, GT Solar International, and DDI. The top after-market NASDAQ stock market losers are: SuperMedia, Human Genome Sciences, China Electric Motor, Neutral Tandem, and ArQule.
Oppenheimer has initiated coverage on China's ShangPharma with an outperform rating and price target of $17, saying the company is well positioned to benefit from the rising Chinese clinical/contract research organization (CRO) industry.
The top pre-market NASDAQ stock market losers are: RINO International, Bank of Kentucky Financial, Human Genome Sciences, EDAP TMS, Patterson-UTI Energy, JA Solar Holdings, GT Solar International, Syntel, Acergy, and Sina.
